Ruxolitinib
- PDF / 169,880 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 24 Downloads / 159 Views
1 S
Ruxolitinib Coccidioidomycosis: 5 case reports
In a retrospective study conducted between 1 January 2007 and 25 May 2019, five men aged 64–84 years were described, who developed Coccidioidomycosis (n=1) and multisite disseminated Coccidioidomycosis (n=3) during treatment with ruxolitinib for myelofibrosis or graft versus host disease (GVHD). Five men, who had myelofibrosis or GVHD, received treatment with ruxolitinib 5–20 mg twice per day [routes not stated]. One of the five men had history of Coccidioidomycosis treated by unspecified antifungal. After 1 month–2 years following initiation of ruxolitinib, men developed Coccidioidomycosis of bilateral pulmonary nodules (n=1), Coccidioidomycosis of skin (n=1), while the remaining three patients developed multisite disseminated Coccidioidomycosis including: retropharyngeal abscess and bony erosions of scapula and vertebrae (n=1), vertebrae and skin (n=1) and liver and spleen (n=1). Coccidioidal complement-fixing titre was
Data Loading...
